Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 Phase 2 RCT Results

被引：0
|
作者：
Taylor, Peter C. [1 ]
de Vlam, Kurt [2 ]
Mease, Philip J. [3 ,4 ]
Peloso, Paul M. [5 ]
Wetzel, Dieter [6 ]
Lertratanakul, Apinya [7 ]
Brun, Nikolai [8 ]
Wiens, Brian [9 ]
Brandt-Juergens, Jan
Drescher, Edit [10 ]
Dokoupilova, Eva [11 ,12 ]
Rowinska-Osuch, Anna [13 ]
Martin, Nadia Abdel-Kader [14 ]
Behrens, Frank [15 ,16 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] ACELYRIN INC, Naples, FL USA
[6] Toclinco GmbH, Freiburg, Germany
[7] ACELYRIN, Chicago, IL USA
[8] Affibody AB, Solna, Sweden
[9] ACELYRIN Inc, Half Moon Bay, CA USA
[10] Csolnoky Ferenc Hosp, Vital Med Ctr Private Clin, Veszprem, Hungary
[11] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno, Czech Republic
[12] MED PLUS Sro, Brno, Czech Republic
[13] ETG Warszawa, Warsaw, Poland
[14] Hosp Quironsalud Infanta Luisa, Seville, Spain
[15] Goethe Univ, Div Rheumatol, Univ Hosp, Frankfurt, Germany
[16] Fraunhofer Inst Translat Med & Pharmacol, Frankfurt, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1431
引用
收藏
页码：2814 / 2816
页数：3
相关论文
共 50 条
  • [1] Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
    Taylor, Peter
    Behrens, Frank
    Mease, Philip J.
    Wetzel, Dieter
    Peloso, Paul
    Brun, Nicolai
    Wiens, Brian
    Brandtjuergens, Jan
    Drescher, Edit
    Dokoupilova, Eva
    Rowinska-Osuch, Anna
    Martin, Nadia Abdel-Kader
    de Vlam, Kurt
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 376 - 379
  • [2] NETAKIMAB, AN IL-17 INHIBITOR, IMPROVES PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 3-YEAR RESULTS OF THE PATERA STUDY
    Korotaeva, Tatiana
    Mazurov, V.
    Gaydukova, I.
    Samtsov, A.
    Khayrutdinov, V.
    Bakulev, A.
    Kokhan, M.
    Kunder, E.
    Soroka, N.
    Eremeeva, A.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [3] Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Hendrikx, Thijs
    Kudlacz, Elizabeth
    Graham, Daniela
    Wu, Joseph
    Cappelleri, Joseph C.
    Hsu, Ming-Ann
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [4] Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
    Gossec, Laure
    Mease, Philip
    Gottlieb, Alice
    Assudani, Deepak
    Coarse, Jason
    Ink, Barbara
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] Etanercept improves psoriatic arthritis patient-reported outcomes: Results from EDUCATE
    Frankel, Ellen H.
    Strober, Bruce E.
    Crowley, Jeffrey J.
    Fivenson, David P.
    Woolley, J. Michael
    Yu, Elaine B.
    Xia, Hong A.
    Chiou, Chiun-Fang
    Stevens, Seth R.
    CUTIS, 2007, 79 (04): : 322 - 326
  • [6] IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
    Behrens, F.
    Taylor, P. C.
    Wetzel, D.
    Brun, N. C.
    Brandt-Juergens, J.
    Drescher, E.
    Dokoupilova, E.
    Rowinska-Osuch, A.
    Martin, N. Abdel-Kader
    de Vlam, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 170 - 171
  • [7] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: Results from two phase 3 studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose
    Mease, Philip
    Gladman, Dafna
    Hendrikx, Thijs
    Graham, Daniela
    Wu, Joseph
    Chen, Linda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB109 - AB109
  • [8] EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
    Strand, V.
    de Vlam, K.
    Covarrubias-Cobos, J. A.
    Mease, P. J.
    Gladman, D. D.
    Hendrikx, T.
    Kudlacz, E.
    Graham, D.
    Wu, J.
    Chen, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1335 - 1336
  • [9] Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
    Dasgupta, B.
    Bertin, P.
    Settas, L.
    Fonseca, J. E.
    Wolff, V.
    Yao, R.
    Govoni, M.
    Vastesaeger, N.
    Weng, H. H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S209 - S209
  • [10] EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
    Coates, Laura C.
    Mease, Philip J.
    Gladman, Dafna D.
    van den Bosch, Filip
    Tasset, Chantal
    Meuleners, Luc
    Besuyen, Robin
    Gao, Jingjing
    Trivedi, Mona
    Hendrikx, Thijs
    Helliwell, Philip
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1269 - 1270
12345